News

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.

03/06/2025

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million.

02/26/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is bioAffinity Technologies, Inc. (BIAF) a buy, sell, or hold?

bioAffinity Technologies, Inc. (BIAF) can sell. Click on Rating Page for detail.

What is bioAffinity Technologies, Inc.'s stock price?

The price of bioAffinity Technologies, Inc. (BIAF) is 0.35 and it was updated on 2025-03-13 13:00:23.

Is bioAffinity Technologies, Inc. (BIAF) overvalued or undervalued?

Currently bioAffinity Technologies, Inc. (BIAF) is in undervalued.

News

From:

To:

News
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million JERSEY CITY, N.J. , Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants"). Tue, Feb. 25, 2025
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million. Tue, Feb. 25, 2025
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges. Thu, Feb. 06, 2025
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Fri, Jan. 10, 2025
Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies President and CEO Maria Zannes will be featured on RedChip Companies' investor webinar on Thursday, Dec. 19. Tue, Dec. 17, 2024

SEC Filings

SEC Filings
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/07/2025
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 02/27/2025
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 02/25/2025
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 02/07/2025
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 01/14/2025
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 01/14/2025
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 12/23/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 12/20/2024
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 12/09/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 12/09/2024
bioAffinity Technologies, Inc. (BIAF) - S-1 SEC Filings 11/27/2024
bioAffinity Technologies, Inc. (BIAF) - DEF 14A SEC Filings 11/22/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 11/22/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 11/14/2024
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 11/14/2024
bioAffinity Technologies, Inc. (BIAF) - PRE 14A SEC Filings 11/12/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 11/05/2024
bioAffinity Technologies, Inc. (BIAF) - D SEC Filings 10/29/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/21/2024
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 10/21/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/10/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/09/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/07/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 09/23/2024
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 09/20/2024
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 09/20/2024
bioAffinity Technologies, Inc. (BIAF) - S-1 SEC Filings 09/11/2024
bioAffinity Technologies, Inc. (BIAF) - DEF 14A SEC Filings 09/05/2024
bioAffinity Technologies, Inc. (BIAF) - PRE 14A SEC Filings 08/23/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 08/23/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 08/14/2024
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 08/14/2024
bioAffinity Technologies, Inc. (BIAF) - D SEC Filings 08/12/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 08/05/2024
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 08/05/2024
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 08/02/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 07/09/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 07/02/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 06/14/2024
bioAffinity Technologies, Inc. (BIAF) - S-8 SEC Filings 06/05/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 06/05/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 05/22/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 05/16/2024
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 05/15/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 04/24/2024
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 04/17/2024
bioAffinity Technologies, Inc. (BIAF) - 424B3 SEC Filings 04/17/2024
bioAffinity Technologies, Inc. (BIAF) - DEFA14A SEC Filings 04/15/2024
bioAffinity Technologies, Inc. (BIAF) - DEF 14A SEC Filings 04/15/2024
bioAffinity Technologies, Inc. (BIAF) - ARS SEC Filings 04/15/2024
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 04/08/2024
bioAffinity Technologies, Inc. (BIAF) - POS AM SEC Filings 04/05/2024
bioAffinity Technologies, Inc. (BIAF) - S-1 SEC Filings 04/04/2024
bioAffinity Technologies, Inc. (BIAF) - PRE 14A SEC Filings 04/02/2024
bioAffinity Technologies, Inc. (BIAF) - POS AM SEC Filings 04/02/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 04/01/2024
bioAffinity Technologies, Inc. (BIAF) - 10-K - Current report SEC Filings 04/01/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 03/29/2024
bioAffinity Technologies, Inc. (BIAF) - D SEC Filings 03/20/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/13/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/08/2024
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 03/08/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/05/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 02/02/2024
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 01/31/2024
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 01/24/2024
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 12/08/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 12/05/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 11/30/2023
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 11/28/2023
bioAffinity Technologies, Inc. (BIAF) - 424B5 SEC Filings 11/28/2023
bioAffinity Technologies, Inc. (BIAF) - S-3 SEC Filings 11/16/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 11/15/2023
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 11/14/2023
bioAffinity Technologies, Inc. (BIAF) - S-8 POS SEC Filings 11/03/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K/A - Current report SEC Filings 11/03/2023
bioAffinity Technologies, Inc. (BIAF) - S-8 SEC Filings 10/18/2023
bioAffinity Technologies, Inc. (BIAF) - SC 13G SEC Filings 10/10/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/10/2023
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 09/26/2023
bioAffinity Technologies, Inc. (BIAF) - RW SEC Filings 09/25/2023
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 09/25/2023
bioAffinity Technologies, Inc. (BIAF) - S-1 SEC Filings 09/20/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 09/20/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 08/14/2023
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 08/14/2023
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 08/11/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 07/28/2023
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 07/06/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 06/07/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 05/15/2023
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 05/15/2023
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 05/11/2023
bioAffinity Technologies, Inc. (BIAF) - DEF 14A SEC Filings 05/01/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 05/01/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 04/25/2023
bioAffinity Technologies, Inc. (BIAF) - PRE 14A SEC Filings 04/20/2023
bioAffinity Technologies, Inc. (BIAF) - S-8 SEC Filings 04/19/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 04/05/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 04/03/2023
bioAffinity Technologies, Inc. (BIAF) - 10-K - Current report SEC Filings 03/31/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/28/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K/A - Current report SEC Filings 03/24/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 03/24/2023
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 03/07/2023
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 03/07/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 02/13/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 01/24/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 01/04/2023
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 12/15/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 12/05/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 12/05/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 12/02/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 12/02/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 12/01/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 11/29/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 11/29/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 11/22/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 11/22/2022
bioAffinity Technologies, Inc. (BIAF) - 10-Q - Quarterly Report SEC Filings 11/14/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 11/10/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 11/08/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 11/08/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 11/08/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/25/2022
bioAffinity Technologies, Inc. (BIAF) - 4 SEC Filings 10/21/2022
bioAffinity Technologies, Inc. (BIAF) - 3 SEC Filings 10/21/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 10/12/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 09/28/2022
bioAffinity Technologies, Inc. (BIAF) - 8-K - Current report SEC Filings 09/06/2022
bioAffinity Technologies, Inc. (BIAF) - 424B4 SEC Filings 09/02/2022
bioAffinity Technologies, Inc. (BIAF) - EFFECT SEC Filings 08/29/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/26/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/25/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/24/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/23/2022
bioAffinity Technologies, Inc. (BIAF) - 8-A12B/A SEC Filings 08/23/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 08/18/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/10/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/09/2022
bioAffinity Technologies, Inc. (BIAF) - CERT SEC Filings 08/09/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 08/08/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 08/05/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 08/02/2022
bioAffinity Technologies, Inc. (BIAF) - 8-A12B SEC Filings 08/02/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 07/28/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 07/27/2022
bioAffinity Technologies, Inc. (BIAF) - UPLOAD SEC Filings 07/11/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 06/16/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 06/16/2022
bioAffinity Technologies, Inc. (BIAF) - UPLOAD SEC Filings 06/08/2022
bioAffinity Technologies, Inc. (BIAF) - FWP SEC Filings 05/26/2022
bioAffinity Technologies, Inc. (BIAF) - S-1/A SEC Filings 05/25/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 05/25/2022
bioAffinity Technologies, Inc. (BIAF) - UPLOAD SEC Filings 05/10/2022
bioAffinity Technologies, Inc. (BIAF) - S-1 SEC Filings 04/25/2022
bioAffinity Technologies, Inc. (BIAF) - CORRESP SEC Filings 04/25/2022
bioAffinity Technologies, Inc. (BIAF) - UPLOAD SEC Filings 03/15/2022
bioAffinity Technologies, Inc. (BIAF) - DRS SEC Filings 02/14/2022
bioAffinity Technologies, Inc. (BIAF) - D SEC Filings 07/26/2017

Press Releases

StockPrice Release
Bioaffinity technologies announces targeted actions to cut $4 million in costs and drive cypath® lung sales growth 03/06/2025
Bioaffinity technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million 02/26/2025
Wallachbeth capital announces bioaffinity technologies warrant inducement for aggregate gross proceeds of $1.4 million 02/25/2025
Bioaffinity technologies announces warrant inducement for aggregate gross proceeds of $1.4 million 02/25/2025
Enlivex therapeutics and bioaffinity technologies interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 01/10/2025
Join bioaffinity technologies' exclusive live investor webinar and q&a session on thursday, december 19 12/17/2024
Bioaffinity technologies appoints new chief science officer to spearhead product development 11/04/2024
Wallachbeth capital announces closing of bioaffinity technologies $2.6 million registered direct offering & concurrent private placement 10/21/2024
Bioaffinity technologies announces closing of $2.6 million registered direct offering & concurrent private placement 10/21/2024
Wallachbeth capital announces pricing of bioaffinity technologies $2.66 million registered direct offering & concurrent private placement 10/18/2024
Bioaffinity technologies announces pricing of $2.66 million registered direct offering & concurrent private placement 10/18/2024
Bioaffinity technologies awarded u.s. federal supply schedule contract for cypath® lung test 10/09/2024
Wallachbeth capital announces closing of bioaffinity technologies registered direct offering and concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million 08/05/2024
Bioaffinity technologies announces closing of registered direct offering, concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million 08/05/2024
Wallachbeth capital announces bioaffinity technologies pricing of registered direct offering and concurrent private placement and warrant inducement for aggregate gross proceeds of $1.75 million 08/02/2024
Biotricity and bioaffinity technologies interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 07/12/2024
Biovie and bioaffinity technologies interviews to air on the redchip small stocks, big money(tm) show on bloomberg tv 07/05/2024
Bioaffinity technologies reports accelerating growth of physician practices ordering cypath® lung tests 06/12/2024
Bioaffinity technologies reports record q1 revenue driven by accelerating growth of cypath® lung sales and increased laboratory volumes 05/15/2024
Bioaffinity technologies news update 05/02/2024
Bioaffinity technologies advances new product development initiatives to accelerate next phase of growth 04/24/2024
Bioaffinity technologies expands campaign to support american cancer society initiative for lung cancer screening 04/09/2024
Wallachbeth capital announces closing of bioaffinity technologies $2.5 million registered direct offering and concurrent private placement 03/08/2024
Bioaffinity technologies announces closing of $2.5 million registered direct offering and concurrent private placement 03/08/2024
Wallachbeth capital announces pricing of bioaffinity technologies $2.5 million registered direct offering and concurrent private placement 03/06/2024
Bioaffinity technologies announces pricing of $2.5 million registered direct offering and concurrent private placement 03/06/2024
Bioaffinity technologies reports accelerating sales growth of cypath® lung 03/05/2024
Bioaffinity technologies in the news 01/30/2024
Bioaffinity technologies announces award of therapeutic patent for treatment of cancer 01/23/2024
Bioaffinity technologies in the news 01/08/2024
Bioaffinity technologies and biovie interviews to air on the redchip small stocks big money(r) show on bloomberg tv 01/05/2024
Bioaffinity technologies appoints jamie platt, ph.d., to its board of directors 12/05/2023
Cms posts final payment determination for bioaffinity technologies' cypath® lung effective january 2024 11/30/2023
Bioaffinity technologies vp david elzi, ph.d., named to american society for cell biology post 11/28/2023
Bioaffinity technologies teams with american cancer society to raise funds for lung cancer screening 11/15/2023
Bioaffinity technologies reports third quarter 2023 financial results and provides business update 11/14/2023
Bioaffinity technologies to present at the 8th annual dawson james small cap growth conference 10/10/2023
Bioaffinity technologies to participate in the h.c. wainwright global investment conference 09/07/2023
Bioaffinity technologies reports second quarter 2023 financial results and provides business update 08/14/2023
Ama issues cpt code for bioaffinity technologies' cypath® lung test for early-stage lung cancer 07/12/2023
Bioaffinity technologies reports fourth quarter and full year 2022 financial results 03/31/2023
Bioaffinity technologies announces publication of results of clinical trial in peer-reviewed journal respiratory research 01/24/2023
Argus research initiates equity research report coverage on bioaffinity technologies, inc. (nasdaqcm: biaf) 12/19/2022
Bioaffinity technologies expands diagnostic division with promotions and new hires to strengthen clinical bench 12/15/2022
Bioaffinity technologies reports third quarter 2022 financial results and provides business update 11/14/2022
Bioaffinity technologies to report third quarter 2022 financial results 11/08/2022
Bioaffinity technologies announces award of therapeutic patents in china, mexico and australia 10/25/2022
Bioaffinity technologies presents results from flow cytometry analysis of the lung at chest conference 10/12/2022
Bioaffinity technologies receives additional $7.7m from exercise of warrants, total capital from public offering increases to approximately $15.6m 09/28/2022
Bioaffinity technologies publishes peer-reviewed results of high-throughput flow cytometry use for evaluating lung health in plos one 09/14/2022
Wallachbeth capital announces closing of bioaffinity technologies, inc. $7.8 million initial public offering 09/06/2022
Bioaffinity technologies, inc. announces closing of $7.8 million initial public offering 09/06/2022

More Headlines

News
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies promotes Senior VP William Bauta, Ph.D., to Chief Science Officer to spearhead product development. 11/04/2024
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement JERSEY CITY, N.J. , Oct. 21, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its previously announced registered direct offering with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock at a price of $1.30 per share and concurrent private placement of common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share for gross proceeds of $2,662,782 before deducting placement agent fees and other offering expenses payable by the Company. 10/21/2024
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $2.6 million registered direct offering and concurrent private placement. 10/21/2024
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement JERSEY CITY, N.J. , Oct. 18, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has entered into a securities purchase agreement with institutional investors for the purchase and sale of 2,048,294 shares (the "Shares") of common stock in a registered direct offering at a price of $1.30 per share and, in a concurrent private placement, common warrants (the "Warrants") to purchase up to 2,662,782 shares of common stock at an exercise price of $1.50 per common share. 10/18/2024
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $2.66 million registered direct offering and concurrent private placement. 10/18/2024
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at risk for lung cancer. 10/09/2024
WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million JERSEY CITY, N.J. , Aug. 5, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that in connection with the BioAffinity Technologies (NASDAQ: BIAF) warrant exercise agreements dated August 2, 2024, with three existing accredited investors, such accredited investors have exercised outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants") at an exercise price that was reduced from $1.64 to $1.25 per share, for gross cash proceeds of approximately $1,302,083 and in consideration of such exercise, the exercising holders received in a private placement new unregistered warrants (the "New Warrants") to purchase up to an aggregate of 1,302,083 shares of common stock (equal to 125% of the shares of common stock issued in connection with the exercise of the Existing Warrants). 08/05/2024
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of registered direct offering, private placement and warrant inducement for gross proceeds of $1.75 million. 08/05/2024
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million JERSEY CITY, N.J. , Aug. 2, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF) (the "Company") has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 1,041,667 of the Company's shares of common stock (the "Existing Warrants"). 08/02/2024
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). 07/12/2024
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). 07/05/2024
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a 139% growth in the number of pulmonology practices and physicians ordering CyPath Lung for their patients. 06/12/2024
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung. 05/15/2024
bioAffinity Technologies News Update SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society. 05/02/2024
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD. 04/24/2024
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening. 04/09/2024
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share. 03/08/2024
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million. 03/08/2024
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NASDAQ: BIAF; BIAFW) has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.5625 per common share. 03/06/2024
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors. 03/06/2024
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months. 03/05/2024
bioAffinity Technologies In The News SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies. 01/30/2024
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment. 01/23/2024
bioAffinity Technologies In the News SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer. 01/08/2024
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). 01/05/2024
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors. 12/05/2023
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024 SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year. 11/30/2023
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology. 11/28/2023
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas. 11/15/2023
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update. 11/14/2023
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week. 10/10/2023
bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13. 09/07/2023
bioAffinity Technologies to Report Third Quarter 2022 Financial Results SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m. 11/08/2022
Stock Market Today: What Happened & 3 Penny Stocks To Watch Now What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 09/29/2022
7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life changing profits. 09/29/2022
Penny Stocks to Buy in a Bear Market? 3 to Watch Right Now Are these penny stocks on your watchlist today? The post Penny Stocks to Buy in a Bear Market? 09/29/2022
Why Is BioAffinity (BIAF) Stock Up 40% Today? Early diagnosis specialist BioAffinity (NASDAQ: BIAF ) spiked 60% on Wednesday morning before paring back some gains in the afternoon to around 40% up. Investors piled into BIAF stock upon the underlying company disclosing the receipt of approximately $7.7 million in additional gross proceeds from its initial public offering (IPO). 09/28/2022
What Is Going on With bioAffinity (BIAF) Stock Today? Source: CI Photos / Shutterstock.com BioAffinity (NASDAQ: BIAF ) stock is rising higher on Wednesday after the cancer diagnostic company announced the publication of its research in PLOS ONE . This was published under the title Sputum analysis by flow cytometry; an effective platform to analyze the lung environment. 09/14/2022
bioAffinity (BIAF) Stock Pops 100% in Red-Hot IPO Well, it turns out the initial public offering ( IPO ) market isn't quite dead. The latest IPO to hit the markets today is that of bioAffinity (NASDAQ: BIAF ). 09/01/2022

Unlock

BIAF Ratings Summary

BIAF Quant Ranking